icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Aug 27-29
Digital ILC 2020
Back grey_arrow_rt.gif
Europe's largest meta-analysis on the prevalence of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and advanced fibrosis (F3-F4)
  "NAFLD is defined as the presence of 5% of hepatic steatosis (HS), in the absence of competing liver disease etiologies. Although NAFLD is very common, a smaller subgroup of these patients can develop nonalcoholic steatohepatitis....The only clinical marker associated with overall mortality and liver-related morbidity in NAFLD and NASH is the presence of advanced fibrosis.3 (NASH).....The overall NAFLD prevalence estimated in the random effects meta-analysis model was 27.6% (95% CI 24.4 - 31.0).....An estimated 64.3% (95% CI 52.7 - 74.4) of the biopsy-proven [NAFLD] patients had NASH.....The overall advanced fibrosis prevalence among general population was 6.1% (95% CI 4.3 - 8.7)."
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Petta S1, Hagström H2, Geier A3, Ratziu V4, Caballeria L5, Expósito C6, Hernández R7, Blokzijl H8, de Knegt RJ9, Ferrinho D10, Ntalla I10, Smith A10, Ramroth H10, Newsome PN11

1Section of Gastroenterology and Hepatology, PROMISE, Policlinico Universitario Paolo Giaccone, Piazza delle Cliniche 2, 90127 Palermo, Italy; 2 Centre for Digestive Diseases, Division of Hepatology, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden; 3Division of Hepatology, Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany; 4Sorbonne Universite, Hopital
Pitie Salpetriere, ICAN, Paris, France; 5Centro d'Investigaciones Biomedicas en Red, Enfermedades Hepatologia y Digestivas (CIBEReHD), Barcelona, Spain; Unitat de Suport a la Recerca (USR) Metropolitana Nord, Institut d'Investigació en Atenció Primària (IDIAP) Jordi Gol, Barcelona, Spain; 6USR Metropolitana Nord, IDIAP Jordi Gol, ICS Institut Català de la Salut, Spain; 7Centre d'Assistencia Primària La Marina, Institut Catalana de la Salut (ICS), Barcelona, Catalonia, Spain; 8Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; 9Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands; 10Gilead Sciences Europe, Ltd, United Kingdom; 11National Institute for Health Research Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, UK